BMY vs. JNJ, ABBV, MRK, PFE, ZTS, RPRX, JAZZ, CORT, PRGO, and SUPN
Should you be buying Bristol-Myers Squibb stock or one of its competitors? The main competitors of Bristol-Myers Squibb include Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), Perrigo (PRGO), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "pharmaceuticals" industry.
Bristol-Myers Squibb vs.
Bristol-Myers Squibb (NYSE:BMY) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, risk, valuation, analyst recommendations, dividends, earnings and profitability.
Johnson & Johnson has higher revenue and earnings than Bristol-Myers Squibb. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.
Bristol-Myers Squibb pays an annual dividend of $2.48 per share and has a dividend yield of 4.3%. Johnson & Johnson pays an annual dividend of $4.96 per share and has a dividend yield of 3.4%. Bristol-Myers Squibb pays out -69.1% of its earnings in the form of a dividend. Johnson & Johnson pays out 71.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb has increased its dividend for 16 consecutive years and Johnson & Johnson has increased its dividend for 63 consecutive years. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and lower payout ratio.
Johnson & Johnson has a net margin of 19.14% compared to Bristol-Myers Squibb's net margin of -15.30%. Johnson & Johnson's return on equity of 35.45% beat Bristol-Myers Squibb's return on equity.
76.4% of Bristol-Myers Squibb shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 0.1% of Bristol-Myers Squibb shares are held by insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Bristol-Myers Squibb currently has a consensus price target of $55.64, suggesting a potential downside of 2.94%. Johnson & Johnson has a consensus price target of $174.73, suggesting a potential upside of 20.95%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, analysts plainly believe Johnson & Johnson is more favorable than Bristol-Myers Squibb.
Bristol-Myers Squibb has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.
In the previous week, Bristol-Myers Squibb had 10 more articles in the media than Johnson & Johnson. MarketBeat recorded 29 mentions for Bristol-Myers Squibb and 19 mentions for Johnson & Johnson. Johnson & Johnson's average media sentiment score of 0.93 beat Bristol-Myers Squibb's score of 0.75 indicating that Johnson & Johnson is being referred to more favorably in the news media.
Johnson & Johnson received 27 more outperform votes than Bristol-Myers Squibb when rated by MarketBeat users. However, 66.20% of users gave Bristol-Myers Squibb an outperform vote while only 65.15% of users gave Johnson & Johnson an outperform vote.
Summary
Johnson & Johnson beats Bristol-Myers Squibb on 16 of the 22 factors compared between the two stocks.
Get Bristol-Myers Squibb News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bristol-Myers Squibb Competitors List
Related Companies and Tools
This page (NYSE:BMY) was last updated on 12/21/2024 by MarketBeat.com Staff
Free BMY Stock Alerts